Literature DB >> 17611726

[Guideline satisfying therapy for chronic heart failure].

U C Hoppe1.   

Abstract

Chronic heart failure may be caused by systolic pump failure and/or impairment of diastolic filling of the ventricles. The standard pharmacotherapy for systolic heart failure includes an ACE inhibitor, betablocker, diuretics and, in patients with severe symptoms, a low dose aldosterone antagonist. An AT1 receptor blocker is indicated for those patients who do not tolerate ACE inhibitors. If patients remain in the functional class NYHA III-IV despite optimal medication and have cardiac dyssynchrony, biventricular pacing may improve the symptoms and prognosis. While evidence-based treatment significantly reduces morbidity and mortality in systolic heart failure, hardly any results from clinical trials are available for diastolic heart failure. Therefore, therapy in patients with diastolic heart failure remains in most cases empirical.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611726     DOI: 10.1007/s00108-007-1898-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology.

Authors:  Willem J Remme; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2002-01       Impact factor: 15.534

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Outcome of heart failure with preserved ejection fraction in a population-based study.

Authors:  R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Authors:  Henry Krum; Ellen B Roecker; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Andrew J S Coats; Hugo A Katus; Michael B Fowler; Milton Packer
Journal:  JAMA       Date:  2003-02-12       Impact factor: 56.272

7.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

Authors:  Maria Rosa Costanzo; Maya E Guglin; Mitchell T Saltzberg; Mariell L Jessup; Bradley A Bart; John R Teerlink; Brian E Jaski; James C Fang; Erika D Feller; Garrie J Haas; Allen S Anderson; Michael P Schollmeyer; Paul A Sobotka
Journal:  J Am Coll Cardiol       Date:  2007-01-26       Impact factor: 24.094

8.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

9.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.